Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7913-01 magrolimab dose-escalation in advanced solid tumors
jRCT2080225170Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2020
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magrolimab in Non-hematologic malignancy, sponsored by Ono Pharmaceutical. Started Apr 2020; status: completed.
02
Drugs
magrolimab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080225170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225170.